Regenxbio Inc is a renowned biotechnology company specializing in the development of life-changing gene therapies for patients suffering from severe diseases. The company's core values revolve around innovation, scientific excellence, and patient-centric focus. Regenxbio Inc is dedicated to improving the lives of individuals by harnessing the power of gene therapy to address unmet medical needs. With a commitment to integrity, collaboration, and transparency, Regenxbio Inc strives to bring groundbreaking treatments to patients, build strong partnerships, and continuously push the boundaries of scientific discovery. Their corporate philosophy embodies a relentless pursuit of transformative therapies to revolutionize healthcare and provide hope for those in need.

Regenxbio Inc is primarily present in the United States.

Regenxbio Inc has achieved several significant milestones in its history. One notable milestone is the successful completion of a Phase I clinical trial for its lead product candidate, RGX-314. This novel gene therapy aims to treat wet age-related macular degeneration (AMD). Additionally, Regenxbio has entered into partnerships with renowned pharmaceutical companies, including Novartis and Audentes Therapeutics, to further expand its gene therapy platform. The company has also garnered regulatory approvals for its gene therapy products, including FDA breakthrough therapy designation for RGX-314. These achievements highlight Regenxbio's commitment to developing innovative gene therapies for various genetic disorders, including eye diseases.

Regenxbio Inc. is a biotechnology company focused on the development and commercialization of gene therapy treatments. Founded in 2008, Regenxbio has grown into a leading player in the field of gene therapy, with a strong emphasis on adeno-associated virus (AAV) vector technology. The company has developed a proprietary NAV Technology Platform, which enables the precise and targeted delivery of therapeutic genes to specific cells in the body. Regenxbio has made significant strides in advancing gene therapy treatments for various genetic disorders, including ophthalmic, metabolic, and neurodegenerative diseases. As an innovative and pioneering company, Regenxbio is committed to revolutionizing the future of gene therapies.

The main competitors of Regenxbio Inc in the market include other gene therapy companies such as bluebird bio, Sangamo Therapeutics, uniQure, and Spark Therapeutics.

Regenxbio Inc is primarily active in the biotechnology industry.

The business model of Regenxbio Inc is focused on developing and commercializing gene therapy treatments for various genetic diseases. Regenxbio utilizes its proprietary adeno-associated virus (AAV) gene delivery platform, which enables targeted and precise gene therapy delivery to specific cells in the body. This versatile platform allows Regenxbio to address a wide range of genetic disorders, including neurodegenerative diseases, metabolic disorders, and ophthalmic diseases. By leveraging their expertise in gene therapy and collaborating with partners, Regenxbio aims to bring effective and innovative treatments to patients with unmet medical needs.

The Regenxbio P/E ratio is -1.85.

The Regenxbio P/S ratio is 4.4.

The AlleAktien quality score for Regenxbio is 4/10.

The expected Regenxbio revenue is 98.58 M USD.

The expected Regenxbio profit is -233.96 M USD.

Regenxbio Inc is a biopharmaceutical company focused on the development of gene therapies for rare genetic diseases. The company's business model is based on the discovery, development, and commercialization of innovative gene therapies to improve the lives of patients worldwide. Regenxbio was founded in 2009 and is headquartered in Rockville, Maryland (USA). As a pioneer in the field of gene therapy, the company has developed an extensive platform based on AAV vector technology. This platform allows Regenxbio to develop customized gene therapies and create new treatment options for patients with rare diseases. Regenxbio's research and development focuses on the identification and characterization of AAV vectors, each capable of transporting and expressing specific genes. Regenxbio has developed a wide range of AAV vectors tailored to the needs of patients with different conditions. The company has partnerships with numerous pharmaceutical and biotech companies such as Novartis, Alexion Pharmaceuticals, and Pfizer. These partnerships focus on the development of gene therapy solutions for various diseases such as cystic fibrosis, hemophilia, and Fabry disease. Regenxbio also has its own pipeline of gene therapy products in various stages of clinical development. Some of the products developed by Regenxbio include: - RGX-314: A gene therapy for the treatment of wet age-related macular degeneration (AMD). This therapy is based on the use of AAV8 vectors to transport the gene for the anti-VEGF antibody into the eye. - RGX-121: A gene therapy for the treatment of mucopolysaccharidosis type II (MPS II). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme iduronate-2-sulfatase (IDS) into the brain. - RGX-111: A gene therapy for the treatment of mucopolysaccharidosis type I (MPS I). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme alpha-L-iduronidase (IDUA) into the brain. - RGX-501: A gene therapy for the treatment of hemophilia A. This therapy is based on the use of AAV8 vectors to transport the gene for factor VIII into the liver. Regenxbio is on its way to becoming one of the leading companies in the gene therapy industry. The customized platform for gene therapy development, close collaboration with partners, and the company's own pipeline of gene therapy products should bring growth and success to the company in the future.

Regenxbio pays a dividend of 0 USD distributed over payouts per year.

The dividend cannot currently be calculated for Regenxbio or the company does not pay out a dividend.

The ISIN of Regenxbio is US75901B1070.

The WKN of Regenxbio is A140E0.

The ticker of Regenxbio is RGNX.

Over the past 12 months, Regenxbio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regenxbio is expected to pay a dividend of 0 USD.

The current dividend yield of Regenxbio is .

Regenxbio pays a quarterly dividend. This is distributed in the months of .

Regenxbio paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

Regenxbio is assigned to the 'Health' sector.

To receive the latest dividend of Regenxbio from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

The last dividend was paid out on 10/3/2024.

In the year 2023, Regenxbio distributed 0 USD as dividends.

The dividends of Regenxbio are distributed in USD.